NCT07784725ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
En resumen
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Fase 32500 participantes buscados220 centros16 países
Categorías
Registrado en 1 registro
- ClinicalTrials.govNCT07784725Abrir este registro en ClinicalTrials.govSincronizado hace 2 semanas
Un mismo estudio puede estar registrado en varios registros. Lo mostramos una sola vez y enlazamos con todos los registros que tenemos.
La información del ensayo se muestra tal como la publicó el registro, en su idioma original.
¿Le interesa este estudio?
Iniciar sesión o cree una cuenta para registrar su interés y seguir este estudio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 212 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.
How this score is built
- Enrolment34/40
2,500 participants (target)
- Site count25/25
212 sites
- Country count15/15
16 countries
- Planned duration8/10
Planned over about 34 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Resumen
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Afecciones
- Obesity or Overweight
Elegibilidad
| Sexo | Todos |
|---|---|
| Edades | 18 Years – Sin máximo |
| Voluntarios sanos | No |
Elegibilidad tal como figura en el registro
Elegibilidad en frases sencillas
Los criterios de este registro aún no se han desglosado en frases separadas. El texto del registro anterior está completo y es la versión autorizada.
Diseño del estudio
| Tipo de estudio | De intervención |
|---|---|
| Fase | Fase 3 |
| Asignación | Aleatorizado |
| Modelo de intervención | PARALLEL |
| Propósito principal | TREATMENT |
| Enmascaramiento | QUADRUPLE (4) |
| Inscripción | 2500 participantes buscados |
Patrocinador y colaboradores
- AstraZeneca Patrocinador
Grupos e intervenciones
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
Intervenciones
- Fármaco Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- Fármaco Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
Variables de resultado
Variable de resultado principal
Percent change in body weight from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in percent body weight change
Plazo 68 weeks
Variable de resultado secundaria
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight
Plazo 68 weeks
Variable de resultado secundaria
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%
Plazo 68 weeks
Variable de resultado secundaria
Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%
Plazo 68 weeks
Variable de resultado secundaria
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on waist circumference change
Plazo 68 weeks
Variable de resultado secundaria
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change
Plazo 68 weeks
Variable de resultado secundaria
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change
Plazo 68 weeks
Variable de resultado secundaria
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants
Plazo 68 weeks
Fechas
| Fecha de inicio | 19 de agosto de 2026 (real) |
|---|---|
| Finalización principal | 11 de agosto de 2028 (estimada) |
| Finalización | 21 de mayo de 2029 (estimada) |
| Primera publicación | 25 de agosto de 2026 (real) |
| Última actualización | 30 de octubre de 2026 |
| Resultados publicados | No indicado en el registro |
| Estado verificado por última vez | octubre de 2026 |
Real significa que el evento ocurrió. Estimada significa que el patrocinador lo prevé. Ambas cosas significan algo distinto.
Ubicaciones
76 centros están en reclutamiento
Argentina
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Research Site | Buenos Aires | En reclutamiento | |
| Research Site | Buenos Aires | En reclutamiento | |
| Research Site | Ciudad de Buenos Aires | En reclutamiento | |
| Research Site | Mendoza | En reclutamiento | |
| Research Site | Ramos Mejía | Aún no recluta | |
| Research Site | Rosario | En reclutamiento | |
| Research Site | San Nicolás | Aún no recluta |
Australia
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Research Site | Botany | En reclutamiento | |
| Research Site | Camberwell | En reclutamiento | |
| Research Site | Charlestown | En reclutamiento | |
| Research Site | St Albans | En reclutamiento | |
| Research Site | St Leonards | En reclutamiento | |
| Research Site | Waitara | En reclutamiento |
Brazil
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Research Site | Belo Horizonte | Aún no recluta | |
| Research Site | Brasília | Aún no recluta | |
| Research Site | Campinas | Aún no recluta | |
| Research Site | Campinas | Aún no recluta | |
| Research Site | Curitiba | Retirado | |
| Research Site | Curitiba | Aún no recluta | |
| Research Site | Curitiba | Aún no recluta | |
| Research Site | Natal | Aún no recluta | |
| Research Site | Porto Alegre | Aún no recluta | |
| Research Site | Rio de Janeiro | Aún no recluta | |
| Research Site | São José dos Campos | Aún no recluta | |
| Research Site | São Paulo | Aún no recluta |
Bulgaria
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Research Site | Montana | Aún no recluta | |
| Research Site | Pleven | Aún no recluta | |
| Research Site | Plovdiv | En reclutamiento | |
| Research Site | Sofia | En reclutamiento | |
| Research Site | Sofia | En reclutamiento | |
| Research Site | Sofia | En reclutamiento | |
| Research Site | Varna | Aún no recluta | |
| Research Site | Yambol | En reclutamiento |
Canada
| Centro | Ciudad | Estado o región | Estado |
|---|---|---|---|
| Research Site | Brampton | Ontario | En reclutamiento |
| Research Site | Calgary | Alberta | En reclutamiento |
| Research Site | Guelph | Ontario | En reclutamiento |
| Research Site | Hamilton | Ontario | En reclutamiento |
| Research Site | Mississauga | Ontario | En reclutamiento |
| Research Site | Moncton | New Brunswick | En reclutamiento |
| Research Site | Montreal | Quebec | En reclutamiento |
| Research Site | New Westminster | British Columbia | En reclutamiento |
| Research Site | North York | Ontario | En reclutamiento |
| Research Site | Québec | Quebec | En reclutamiento |
| Research Site | Québec | Quebec | En reclutamiento |
| Research Site | Saint-Charles-Borromée | Quebec | En reclutamiento |
| Research Site | Scarborough Village | Ontario | En reclutamiento |
| Research Site | Sherbrooke | Quebec | En reclutamiento |
| Research Site | Stoney Creek | Ontario | En reclutamiento |
| Research Site | Stouffville | Ontario | En reclutamiento |
| Research Site | Surrey | British Columbia | Retirado |
En el registro figuran 170 centros más.
Documentos del estudio
No hay documentos enlazados en este registro.
Cambios a lo largo del tiempo
- 30 de octubre de 2026
Centro añadido
8 sites added (220 total)
212220